Market Analysis on Nontuberculous Mycobacterial Infection Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Forecast for the Nontuberculous Mycobacterial Infection Market from 2024 to 2025?#_x000D_
There has been a robust expansion in the nontuberculous mycobacterial infection market size in the past few years. It is expected to increase from $14.25 billion in 2024 to $15.11 billion in 2025, representing a compound annual growth rate (CAGR) of 6.0%. Factors such as enhanced diagnostics, an older population, awareness of cystic fibrosis, and immunosuppressive drugs have contributed to growth during the historic period._x000D_
_x000D_
#What Is the Projected Market Size of the Nontuberculous Mycobacterial Infection Market?#_x000D_
In the upcoming years, the nontuberculous mycobacterial infection market is projected to witness substantial growth and reach a valuation of $19.57 billion in 2029, expanding at a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this growth during the forecast period include the advancement of antimicrobial drugs, elevated awareness of NTM, progress in genetic research, and the rise of telehealth and remote monitoring. Key trends expected during this period encompass tailored treatment, regulatory emphasis, integrated therapies, and the use of digital health tools._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp_x000D_
_x000D_
#Who are the Major Competitors in the Nontuberculous Mycobacterial Infection Market Outlook?#_x000D_
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC._x000D_
_x000D_
#What Is Fueling Growth in the Nontuberculous Mycobacterial Infection Market?#_x000D_
The growing incidence of chronic obstructive pulmonary disease (COPD) is projected to boost the expansion of the nontuberculous mycobacterial infection market. Chronic obstructive pulmonary disease (COPD) is a persistent respiratory disorder marked by continuous and often worsening limitation of airflow in the lungs. Patients with COPD who develop nontuberculous mycobacterial (NTM) infections are found to experience substantial deterioration of forced expiratory volume in a second (FEV1) with a higher-exacerbation rate. COPD may impair the immune system and cause damage to the lung tissues, thereby making the lungs more susceptible to NTM bacterial infection. For example, in March 2023, a report published by The Scottish Public Health Observatory (ScotPHO), indicated that COPD rates started to surge between 2021 and 2022, with an increase in males from 83.2 to 97.6 per 100,000 people, while in females, it went up from 72.6 to 97.3. Hence, the escalating instances of chronic obstructive pulmonary disease (COPD) is sparking the expansion of the nontuberculous mycobacterial infection market. Additionally, the nontuberculous mycobacterial infection market can be further propelled by the increasing instances of infectious diseases. Infectious diseases, caused by harmful microorganisms including bacteria, viruses, fungi, and parasites, can spread from one person to another, manifesting diverse symptoms and health complications. The growing prevalence of infectious diseases, including those leading to Nontuberculous Mycobacterial (NTM) infections, could potentially fuel the NTM infection market expansion. It could elevate the awareness towards these infections, encourage more regular screening and early detection, increase the endeavour towards R&D for NTM treatments, and elevate the demand for therapies targeting NTM pathogens due to an intensified focus on infectious diseases in healthcare. For example, in November 2024, according to UNICEF, pneumonia was identified as the major infectious disease causing death in more than 700,000 children per year, amounting to approximately 2,000 children every day. Hence, the growing prevalence of infectious diseases is contributing to the growth of the nontuberculous mycobacterial infection market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp_x000D_
_x000D_
#Which Nontuberculous Mycobacterial Infection Market Segments Are Growing the Fastest?#_x000D_
The nontuberculous mycobacterial infection market covered in this report is segmented –_x000D_
_x000D_
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes_x000D_
2) By Route Of Administration: Oral, Parenteral, Other Routes_x000D_
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
_x000D_
Subsegments:_x000D_
1) By Macrolides: Azithromycin, Clarithromycin_x000D_
2) By Rifampin: Rifampin, Rifabutin_x000D_
3) By Aminoglycoside: Amikacin, Streptomycin_x000D_
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid_x000D_
_x000D_
#Which Industry Trends Are Shaping the Future of the Nontuberculous Mycobacterial Infection Market?#_x000D_
Leading firms in the nontuberculous mycobacterial infection market are employing new approval methods for treatments, such as the fast track designation for drug approval, to maintain their market standing. The Fast Track designation offered by the FDA is a procedure made to accelerate the production and examination of drugs for severe conditions that do not yet have a medical solution. For example, in July 2022, the Food and Drug Administration, an American federal agency, awarded NUZYRA with Fast Track Designation to manage nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), an innovative broad-range antibiotic, was developed to fight serious bacterial infections, including those caused by resistant strains. This designation expedites the development and review of NUZYRA antibiotic, addressing substantial medical needs that are currently unmet._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Countries Are Leading the Nontuberculous Mycobacterial Infection Market?#_x000D_
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the nontuberculous mycobacterial infection market, and how is it changing globally?_x000D_
2. Who are the major companies in the nontuberculous mycobacterial infection market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the nontuberculous mycobacterial infection market right now?_x000D_
4. Which products or customer segments are growing the most in the nontuberculous mycobacterial infection market?_x000D_
5. What factors are helping or slowing down the growth of the nontuberculous mycobacterial infection market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
